MARS: mutation-adjusted risk score for advanced systemic mastocytosis
1 Bekeken
• 07/09/23
0
0
insluiten
administrator
abonnees
Andreas Reiter, MD, University Medical Centre, Mannheim, Germany, discusses how a mutation-adjusted risk score (MARS) may improve treatment stratification for advanced systemic mastocytosis (AdvSM). This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.
Laat meer zien
Facebook Reacties
SORT BY-
Top Reacties
-
Laatste Reacties